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P U B L I S H E D B Y E L S E V I E R I N C .LETTERS TO THE EDITORArterial 18F-FDG Uptake in Rheumatoid
Arthritis Correlates With Synovial ActivityPrevious studies have demonstrated that patients
with rheumatoid arthritis (RA) have increased risk
of cardiovascular disease (CVD). Although a prior
study has reported an increase in atherosclerotic
plaque inﬂammation in RA patients (1), the relation-
ship between joint inﬂammation and arterial inﬂam-
mation has not been previously reported, to the best
of our knowledge. Further, the contribution of RA to
arterial inﬂammation (after adjusting for CVD risk
factors and statin use) remains unknown.
18F-ﬂuorodeoxyglucose (FDG) positron emission
tomography (PET)/computed tomography (CT) is a
well-established tool that has been used to quantita-
tively assess the burden of inﬂammation inFIGURE 1 Aortic TBR Was Signiﬁcantly Higher in Patients With RA V
(A) Aortic target-to-background ratio (TBR) was signiﬁcantly higher in p
A signiﬁcant correlation was observed between synovial F-ﬂuorodeoxygl
in patients with RA. (C) Higher FDG uptake in the wall of the ascending a
patient with RA in the right shoulder.atherosclerotic plaques (2), risk of future CVD events
(3), and degree of disease activity in RA (4). In this
study, we used FDG-PET/CT imaging to assess: 1)
whether patients with RA have increased arterial FDG
uptake; and 2) whether synovial activity correlates
with arterial FDG uptake. The study population was
identiﬁed from a database of patients imaged for
clinical purposes who were found to be free from
cancer and CVD. First, 33 patients with RA (RA Group)
were identiﬁed on the basis of a clinical diagnosis
derived from the clinical records and then were
matched (1:1) to patients with neither RA nor CVD
(Matched Controls) based on age (6 years) and sex.
Measurement of FDG uptake in aorta and synovial
tissues were performed as previously detailed (2,4).
Synovial activity was measured in glenohumeral,
acromioclavicular, and acetabulofemoral joints, and
recorded as the average of the maximum standard-
ized uptake values (SUVs) (Figure 1D). Additionally,
FDG uptake of subcutaneous adipose tissue (SAT)
was measured as control tissue, and coronaryersus Matched Controls
atients with rheumatoid arthritis (RA) versus matched controls. (B)
ucose (FDG) uptake (a marker of RA disease activity) and arterial TBR
orta in a patient with RA. (D) High synovial activity (FDG uptake) in a
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960calcium scoring was performed for the entire patient
population.
There were no statistically signiﬁcant differences in
age, sex, blood pressure, Framingham Risk Score
(FRS), lipid proﬁle, or statin use between the RA Group
and Matched Controls. Arterial target-to-background
ratio (TBR) was signiﬁcantly higher in RA versus
Matched Controls (2.150.29 vs. 1.840.32; p¼0.001)
(Figures 1A and 1C). This difference remained signiﬁ-
cant after adjusting for age, sex, hypertension, dia-
betes, smoking, dyslipidemia, and body mass index
(b ¼ 0.273; p ¼ 0.001) and after adjusting for statin use,
low-density lipoprotein (LDL) and high-density lipo-
protein (b ¼ 0.297; p ¼ 0.002).
The difference in arterial TBR remained consistent
across subgroup analyses. In patients with FRS <10,
TBR was higher in subjects with RA (2.06  0.25 vs.
1.80  0.17; p ¼ 0.001). Likewise, arterial TBR
remained signiﬁcantly higher in the RA Group in
patients: 1) without coronary calcium (p ¼ 0.002); 2)
with LDL <130 mg/dl (p ¼ 0.01); or 3) who were statin
naive (p < 0.001). Because a subset of the patients
were cancer survivors undergoing surveillance scan-
ning, we evaluated the between-group differences
after adjusting for prior cancer chemotherapy and
radiotherapy, and observed a persistent increase in
arterial TBR among those with RA (b ¼ 0.34, p <
0.001).
Moreover, we observed a signiﬁcant correlation
between synovial and arterial FDG uptake (SUV)
in patients with RA (R ¼ 0.42, p ¼ 0.015), but
not in controls (R ¼ 0.28, p ¼ 0.11). This relation-
ship remained signiﬁcant after correcting for
background venous activity (TBR) (R ¼ 0.55, p¼ 0.001)
(Figure 1B). By contrast, there was no signiﬁcant cor-
relation between arterial versus SAT FDG uptake (R ¼
0.17; p ¼ 0.14). We did not observe a correlation be-
tween C-reactive protein levels and arterial (p ¼ 0.67)
or synovial FDG uptake (p ¼ 0.42).
In this study, we demonstrated that patients with
RA have signiﬁcantly higher arterial FDG uptake
compared with matched controls that remained sig-
niﬁcant after adjusting for atherosclerosis risk fac-
tors and statin therapy. Furthermore, we observed a
signiﬁcant correlation between synovial activity and
arterial FDG uptake. Collectively, these ﬁndings
suggest that patients with RA have elevated levels of
arterial inﬂammation beyond that predicted by
traditional risk factors, and that arterial inﬂamma-
tion may be related to the severity of RA disease
activity (measured as synovial activity). Because
arterial FDG uptake has been associated with the risk
of subsequent CVD (at least in patients without RA)
(3), these ﬁndings add to the body of evidencelinking RA disease activity with potentiated risk
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403–10.Delayed Transcatheter Heart Valve
Migration and FailureDelayed downward migration of the SAPIEN trans-
catheter heart valve (THV) (Edwards Lifesciences
Corporation, Irvine, California) is a rare com-
plication after transcatheter aortic valve replace-
ment (TAVR) (1–3). THV migration into the left
ventricle has been described 2 to 43 days after
deployment and is associated with cardiogenic shock
(1,2) or disruption of mitral valve function (3). We
describe 2 additional presentations associated with
delayed downward THV migration: native valve
